Are the pharmacokinetic data of meropenem studied in CSF of a mixed population composed of patients with cerebral infections and patients with extracerebral infections really helpful for clinicians treating CNS infections?

在由脑部感染患者和脑外感染患者组成的混合人群中，对美罗培南脑脊液进行药代动力学研究的数据，对于治疗中枢神经系统感染的临床医生来说，真的有帮助吗？